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CK1 Plays a Central Role in Mediating MDM2 Control of p53
and E2F-1 Protein Stability
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Anne-Sophie Huart‡1, Nicola J. MacLaine‡, David W. Meek§, and Ted R. Hupp‡2
From the ‡Cancer Research UK p53 Signal Transduction Group, University of Edinburgh, Institute of Genetics andMolecular
Medicine, Division of Cancer Biology, Crewe Road South, Edinburgh EH4 2XR, and the §Biomedical Research Centre, Ninewells
Hospital andMedical School, University of Dundee, Dundee DD1 9SY, Scotland, United Kingdom
The ubiquitin ligase murine double minute clone 2 (MDM2)
mediates ubiquitination and degradation of the tumor suppres-
sor p53. The activation and stabilization of p53 by contrast is
maintained by enzymes catalyzing p53 phosphorylation and
acetylation. Casein kinase 1 (CK1) is one such enzyme; it stimu-
lates p53 after transforming growth factor- treatment, irradi-
ation, or DNA virus infection. We analyzed whether CK1 regu-
lates p53 protein stability in unstressed conditions. Depletion of
CK1 using small interfering RNA or inhibition of CK1 using the
kinase inhibitor (D4476) activated p53 and destabilized E2F-1,
indicating that steady-state levels of these proteins are con-
trolled by CK1. Co-immunoprecipitation of endogenous CK1
with MDM2 occurred in undamaged cells, indicating the exist-
ence of a stablemultiprotein complex, and as such, we evaluated
whether the MDM2 Nutlin had similar pharmacological prop-
erties to the CK1 inhibitor D4476. Indeed, D4476 or Nutlin
treatments resulted in the same p53 and E2F-1 steady-state pro-
tein level changes, indicating that the MDM2CK1 complex is
both a negative regulator of p53 and a positive regulator of
E2F-1 in undamaged cells. Although the treatment of cells with
D4476 resulted in a partial p53-dependent growth arrest, the
induction of p53-independent apoptosis by D4476 suggested a
critical role for the MDM2CK1 complex in maintaining E2F-1
anti-apoptotic signaling. These data highlighting a pharmaco-
logical similarity between MDM2 and CK1 small molecule
inhibitors and the fact that CK1 andMDM2 form a stable com-
plex suggest that the MDM2CK1 complex is a component of a
genetic pathway that co-regulates the stability of the p53 and
E2F-1 transcription factors.
The tumor suppressor protein p53 is a key regulatory protein
that prevents proliferation of damaged cells. This central player
in maintaining tissue integrity is present at low levels under
unperturbed conditions but becomes rapidly stabilized and
activated in response to a variety of stimuli such as ionizing
radiation, genome instability, DNA damage, transforming
growth factor-, DNA or RNA virus infection, Type I interfer-
ons, and overexpressed oncogenes (1). p53 responds to these
diverse stresses to regulate many target genes that induce cell
cycle arrest, apoptosis, autophagy, senescence, or DNA repair
or alter metabolism (2). The primary amino acid sequence of
p53 contains many evolutionarily conserved serine, threo-
nine, and lysine residues for which post-translational modi-
fications have a crucial role in p53 stabilization and activa-
tion. Most residues that are phosphorylated are targeted by
many different kinases in response to various stresses when p53
is activated, although some phosphorylations have been re-
ported to be inhibitory (3).
In unstressed cells, p53 is under the negative regulation of the
murine double minute clone 2 (MDM2)3 protein that mediates
the ubiquitination and degradation of p53 by the proteasome
(4). p53 transcriptionally activates themdm2 gene, and because
MDM2 inhibits p53 activity, this forms a negative feedback
loop that tightly regulates p53 function (5). In addition to inac-
tivation of p53-stimulated apoptosis, the oncogenic properties
ofMDM2may in part bemediated by an anti-apoptotic activity
that converts E2F-1 from a negative to a positive regulator of
cell cycle progression by maintaining E2F-1 in a permanent
state of growth stimulation (6).
MDM2 has been dissected intomultiple functional domains:
anN-terminal allosteric hydrophobic pocket that interactswith
specific linear peptide docking motifs in proteins such as p53, a
nuclear localization signal and a nuclear export signal, an acidic
domain that binds the ubiquitin signal in the DNA-binding
domain of p53, a C-terminal RING domain that coordinates E3
functions in ubiquitin transfer, an ATP-binding motif that reg-
ulates the chaperone functions of MDM2, and a pseudo-sub-
stratemotif or lid that regulates its ubiquitin ligase function (7).
Reconstitution of the ubiquitin ligase function of MDM2 has
demonstrated a two-site docking model for modification of
p53. This involves occupation of the N-terminal hydrophobic
pocket ofMDM2by a priming ligand (p53) that induces a dock-
ing event between the acidic domain of MDM2 and a ubiquitin
signal in the DNA-binding domain of p53 (8). Although a sim-
ilar dual-site docking ubiquitination mechanism by MDM2
1 Supported by a Ph.D. studentship from the Cancer Research UK
(C483/A10706).
2 SupportedbyCancerResearchUKProgrammeGrantC483/A6354. Towhom
correspondence should be addressed: University of Edinburgh, Institute of
Genetics and Molecular Medicine, Division of Cancer Biology, CRUK p53
Signal Transduction Group, Crewe Rd. South, Edinburgh EH4 2XR,
Scotland, UK. Tel.: 44-1317773538; Fax: 44-1317773583; E-mail: ted.hupp@
ed.ac.uk.
3 The abbreviations used are: MDM2, murine double minute clone 2; CK1,
casein kinase 1; D4476, 4[4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-5-pyridin-
2-yl-1-H-imidazol-2-yl]benzamidine; Nutlin-3, ()-4-[4,5-Bis(4-chlorophe-
nyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-car-
bonyl]-piperazin-2-one; VRK1, vaccinia-related kinase 1; siRNA, small
interfering RNA; wt, wild type; DMEM, Dulbecco’s modified Eagle’s medi-
um; DMSO, dimethyl sulfoxide; PBS, phosphate-buffered saline; FACS, flu-
orescence-activated cell sorter.
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operates on the interferon regulatory factor-2 transcription fac-
tor (9), it is not clear whether the ubiquitination or chaperone
functions of MDM2 dominate on E2F-1 in cells (10).
Upon DNA damage, p53 is post-translationally modified to
inhibit interactions with MDM2 and to stabilize protein-pro-
tein interactions with transcription factor machinery. Several
kinases also phosphorylate MDM2 and modulate interactions
with p53 in different conditions. Thus p53 and MDM2 inte-
grate signals of multiple signaling pathways by post-transla-
tional modifications. The interaction of both proteins is regu-
lated through their phosphorylation status. CK1 represents a
unique group within the superfamily of serine/threonine-spe-
cific protein kinases that is ubiquitously expressed in eukaryotic
organisms and is evolutionarily conserved. In mammals, seven
distinct genes encoding CK1 isoforms (,, 1, 2, 3, , and )
and their various splice variants are expressed. CK1 activity is
regulated by various mechanisms including subcellular com-
partmentation and, in the case of CK1 and , proteolytic cleav-
age, autophosphorylation, and dephosphorylation of the C ter-
minus. Among the increasing number of CK1 substrates are
enzymes, transcription factors, splice factors, cytoskeleton pro-
teins, receptors, membrane-associated proteins, and cell sig-
naling proteins (11).
Several CK1 isoforms, , , and , have been identified that
phosphorylate the N-terminal phosphorylation sites of p53.
UponDNAdamage orDNAvirus infection, phosphorylation of
p53 at the threonine 18 site by CK1 (12) and the serine 20 site
by CK1 (13), respectively, is believed to attenuate the interac-
tion of p53 with its inhibitory counterpart MDM2 and to stabi-
lize the binding of the co-activator p300, thereby activating p53
function. The interplay between p53 and MDM2 on different
levels is influenced not only by the phosphorylation status of
p53 but also the phosphorylation status of MDM2. Interest-
ingly, CK1 as well as CK1 have been shown, in normal con-
ditions, to phosphorylate several serine residues within the
acidic domain ofMDM2, which are involved in the degradation
of p53 and the binding to other proteins (14). Taken together,
the involvement of CK1, especially CK1, in the regulation of
p53 and MDM2 functions as well as their interplay suggests an
important role of CK1 in modulating the effects of p53 on cell
growth and genome integrity.
Because of the phosphorylation of p53 and MDM2 by some
CK1 isoforms in normal conditions or after DNA damage, and
the link between E2F-1, MDM2, and p53 pathways, we set out
to investigate the effects of CK1 depletion or inhibition on
the expression of key proteins. Our data indicate that CK1, like
MDM2, plays a fundamental role in regulating the steady-state
levels of the p53 and E2F1 tumor suppressor proteins. The
observation that a small molecule inhibitor of CK1 induces cell
death also suggests CK1 might form an attractive target for
anti-cancer therapeutics.
EXPERIMENTAL PROCEDURES
Cell Lines and Treatments—All of the experiments were
performed with the A375 cell line, which is an adherent
human amelanotic malignant melanoma cell line, and/or
with HCT116 wt and p53/ cell lines, which are adherent
human colon carcinoma cell lines. The cell stocks were
maintained in DMEM or McCoy’s 5A, respectively (Invitro-
gen) supplemented with 10% fetal bovine serum (Autogen Bio-
clear). A375 cells were treatedwith x-ray irradiation at a dose of
5 grays using a cabinet x-ray system (Faxitron) and then
returned to the incubator for 1–48 h. Untreated controls were
included. D4476 (Calbiochem) was transfected using Attract-
ene (Qiagen) into the cells as recommended by the supplier.
The cells were treated with 5–40 M of D4476 (final concen-
tration) for 48 h. Mock transfected, DMSO solvent, and
untreated controls were included. Nutlin-3 (Alexis Biochemi-
cals) was used directly by addition to the cell culturemedium at
5 and 10 M (final concentration) for 24 h. DMSO solvent and
untreated controls were included.
Transient Transfection of siRNA—siRNA to specific target
genes was obtained from Dharmacon. The genes targeted were
CK1 (siGENOME SMARTpool against human CSNK1A1
(NM_001892)), CK1 (siGENOME SMARTpool against human
CSNK1D (NM_001893)), VRK1 (siGENOME SMARTpool
against human VRK1 (NM_003384)), and p53 (siGENOME set
of 4 siRNA duplexes against human TP53 (NM_000546)).
siCONTROLnontargeting siRNAPool#2was used as a control.
The cells were transfected using LipofectamineTM 2000
(Invitrogen) according to the manufacturer’s instructions. The
final concentration of siRNA used was 40 nM (or 80 nM when
cells were transfected with two different siRNAs). The cells
were incubated for 72 h. Lipofectamine (mock transfected)
controls and untreated controls (DMEM only) were included.
Western Blotting—The cells were harvested and lysed in urea
buffer (7 M urea, 0.1 M dithiothreitol, 0.05% Triton X-100, 25
mM NaCl, 20 mM HEPES-KOH, pH 7.6, 5 mM NaF, 2 mM
Na3VO4, 2.5 mM Na4P2O7, 1 protease inhibitor mixture).
Proteins (20 or 40 g of lysate) were resolved by denaturing gel
electrophoresis using 10 or 15% polyacrylamide gels in SDS
running buffer. The proteins were transferred to Hybond-C
Extra nitrocellulose membranes (Amersham Biosciences).
The membranes were blocked in 5% (w/v) nonfat dried milk
(Marvel) or 3% (w/v) bovine serum albumin for 1 h at room
temperature and then incubated overnight at 4 °Cwith primary
antibody (Table 1). The membranes were incubated with the
appropriate horseradish peroxidase-conjugated secondary
antibody (DAKO; Santa Cruz Biotechnology) for 1 h at room
temperature. The proteins were detected by incubation with
ECL reagent. The membranes were blotted dry and exposed to
x-ray film (SLS), which was then developed (x-ray imaging
equipment; Fuji).
TABLE 1
Different primary antibodies used for Western Blotting and
co-immunoprecipitation
Target
protein Clone
Primary antibody
type Supplier
-Actin AC-15 Mouse monoclonal Sigma (A5441)
CK1 C-19 Goat polyclonal Santa Cruz Biotechnology (SC-6477)
E2F-1 KH95 Mouse monoclonal Santa Cruz Biotechnology (SC-251)
MDM2 2A10 Mouse monoclonal From Borek Vojtesekb
p21 EA10 Mouse monoclonal Calbiochem (OP64)
pRB G3–245 Mouse monoclonal BD Biosciences Pharmingen (554136)
p53 DO1 Mouse monoclonal From Borek Vojtesekb
p53 CM1a Rabbit polyclonal From Borek Vojtesekb
IRF1 20 Mouse monoclonal BD Biosciences (612047)
a Used only for immunoprecipitation step of p53.
b Department of Experimental Oncology, Masaryk Memorial Cancer Institute,
Brno, Czech Republic.
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Co-immunoprecipitation from Cell Lysates—The cells were
harvested and lysed in co-immunoprecipitation buffer (50 mM
HEPES-NaOH, pH 7.2, 150 mM NaCl, 0.5% Tween 20, 1 pro-
tease inhibitor mixture). The lysates were precleared by incu-
bation with Sepharose CL 4B (Sigma-Aldrich) and protein
G-SepharoseTM 4 FastFlow (GEHealthcare) at 4 °C with gentle
rotation for 40 min. Two g of primary antibody (Table 1) was
incubated with 500 g of protein in the precleared lysate in
a final volume of 200l for 2 h at 4 °Cwith gentle rotation. Two
types of negative control were included: no antibody with pre-
cleared lysate and antibody with co-immunoprecipitation
buffer only. Fifteen l of protein G-Sepharose was then added
to the above samples and incubated for 1 h at 4 °C with gentle
rotation. Supernatant (flow-through) was collected, and the
beads were washed four times with 500 l of co-immunopre-
cipitation buffer. Fifty l of 4 SDS sample buffer containing
0.2 M dithiothreitol was then added to the beads, the samples
were boiled at 95 °C for 5min, and the eluate was collected. The
samples were analyzed by Western blotting.
Cell Cycle Analysis—Treated cells were trypsinized, pelleted,
and resuspended in 300 l of PBS. The PBS cell suspensions
were mixed gently with 5 ml of ice-cold ethanol 70% and incu-
bated at 4 °C overnight. Fixed cells were rehydrated in PBS for
10 min at room temperature and then pelleted by centrifuga-
tion. The cells were resuspended in 300l of PBS containing 50
g/ml propidium iodide (Sigma) and 100 g/ml RNase A
(Sigma-Aldrich). Cell cycle profiles were obtained (from more
than 10,000 cells) using a BDFACSAria II SORP flow cytometer
(BD Biosciences) and analyzed with BD FACSDiva 6 and
FlowJo7 software.
RESULTS
CK1 Depletion Using siRNA Activates p53—We had
recently reported the co-purification of vaccinia-related kinase
1 (VRK1) and casein kinase 1 (CK1) in a screen for virus-in-
duced p53 serine 20 kinases; CK1 was identified as a selective
virus-induced kinase targeting p53 (13). To determine whether
endogenous CK1 or VRK1 plays a role in regulating p53/
MDM2 pathways in cycling cells, we transfected A375 cells
with isoform-specific siRNA againstCK1 (CSNK1A1 gene) or
VRK1, which reduced the level of CK1 or VRK1, respectively,
by 3-fold (Fig. 1). Interferon regulatory factor-1 levels were
assessed to evaluate whether siRNA treatment triggered the
up-regulation of this positive transcription factor for genes
involved in immune response, cell growth regulation, and apo-
ptosis in mammalian cells that can affect the p53 signaling
pathway. The down-regulation of CK1 protein triggered p53,
MDM2, and p21 increase, alongside a dephosphorylation of
pRB (Fig. 1). These changes were not observed after treating
cells with siRNA to VRK1 (Fig. 1).
The previously documented ability of CK1 to induceMDM2
phosphorylation, which might control MDM2 ubiquitination
activity (14), suggested that our results could be due to a dis-
ruption betweenMDM2andp53 binding afterCK1depletion,
leading to an increase of p53 and thus of the p53-inducible gene
products MDM2 and p21. p21 is known for inhibiting cyclin
cyclin-dependent kinase complexes and thus can explain the
dephosphorylated status of pRB when p21 increased. Further-
more, CK1 depletion after siRNA treatment led to a signifi-
cant decrease of E2F-1 (Fig. 1), which might be explained by
disruption of the stabilizing binding between E2F-1 and
MDM2, which has been shown to displace other ubiquitin
ligases from E2F-1 (15).
CK1 Inhibition Using a Specific Kinase Inhibitor Activates
p53—To evaluate whether CK1 kinase activity was generating
these protein level changes in p53 and E2F-1, we analyzed cell
cycle targets using a specific kinase inhibitor. There are three
main chemical inhibitors of CK1 that can be used, one of which,
D4476, shows a more pronounced specificity for CK1 at low
concentrations (16). Upon increasing the addition of D4476 to
A375 cells, there was a dose-dependent reduction in E2F-1 pro-
tein levels (Fig. 2A), slightly more pronounced with 20 M
D4476. Interestingly, pRB simultaneously showed a decrease in
its phosphorylation status (Fig. 2B). A dose-dependent increase
in p53, MDM2, and p21 protein levels was also observed (Fig.
2A). These increases were especially pronounced with a con-
centration of 40 M D4476 (Fig. 2A, lane 7 versus lane 1).
CK1 siRNA Treatment Does Not Activate p53—Because the
D4476 drug has been shown to efficiently inhibit at least
the delta isoform of CK1, we decided to check whether or not the
depletion of CK1 by siRNA treatment triggers the same effects
as CK1 siRNA treatment. CK1 depletion did not generate
any increase of p53 orMDM2protein levels (Fig. 3, lane 4 versus
lane 3). Only p21 levels did increase significantly (Fig. 3). Thus
we can hypothesize that the effects from D4476 treatment on
A375 cells described above areCK1-specific. Nevertheless it is
possible that CK1 siRNA treatment did not trigger what we
expected because CK1 expression is too low in this cell line.
But in this latter case, it means that D4476 effects in the A375
cell line should be indeed mainly because of CK1 inhibition.
FIGURE 1. Effects of CK1depletion using siRNAonp53protein stability.
A375 cells were transfected with control siRNA (40 nM; lane 3), CK1-specific
siRNA (40 nM; lane 4), or VRK1-specific siRNA (40 nM; lane 5) for 72 h. A mock
transfected control (lane 2) and an untreated control (DMEM only; lane 1)
were included. The protein levels were determined byWestern blotting with
antibodies against the indicated proteins. RNAi, RNA interference.
CK1 andMDM2 Form an Active Signaling Complex
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CK1 Depletion Using siRNA Has the Same Physiological
Effect on p53 and E2F-1 Proteins as Ionizing Radiation—We
studied changes in protein levels after the physiological stress of
DNAdamage induced by ionizing radiation. As expected, levels
of p53 rose after exposure to 5 Grays of x-ray as did levels of
MDM2, which is probably p53-dependent because of the feed-
back loop between MDM2 and p53 (Fig. 4A, lanes 1 and 2).
Transactivation of p53 led also to an increasing up-regulation
of p21; E2F-1 levels decreased 24 h after treatment (Fig. 4A,
lanes 1 and 2). As for CK1, the protein levels were not affected
by ionizing radiation over a time course experiment (data not
shown). This result favors the interpretation that CK1 pro-
moter does not present a p53-responsive element, unlike CK1
(11).
Next, we tested whether CK1 siRNA can cooperate with
DNA damage to increase the p53, MDM2, and p21 protein
levels and decrease the E2F-1 protein level (Fig. 4A, lanes 7
and 8, and B). A375 cells were transfected with control
siRNA or CK1 siRNA for 72 h, followed either by a treat-
ment with 5-Gray x-ray or control exposure, and cultured for
a further 24 h. Interferon regulatory factor-1 levels were also
assessed for the same reason as explained above. The results
showed that p53 and MDM2 protein levels were increased
after x-ray in the siRNA controls. These protein levels were
also increased after CK1 siRNA treatment without x-ray
treatment (slightly more than above) but were not further
increased after x-ray treatment. By contrast, the decrease of
E2F-1 protein level was two times more pronounced after
x-ray than without in cells transfected with CK1-specific
siRNA. These data suggest that inhibition of CK1 expres-
sion followed by x-ray treatment shows a synergistic effect
on E2F-1 levels.
E2F-1 Decrease Following CK1 siRNA or D4476 Treatment
Is p53-independent—To determine whether E2F-1 decrease
and MDM2 increase following CK1 siRNA treatment are
dependent on the presence of p53, we first transfected A375
cells with both isoform-specific siRNA against CK1 and iso-
form-specific siRNA against p53. CK1 siRNA treatment trig-
gered the same protein level changes as described above. p53
siRNA treatment alone triggered a decrease of p21 protein level
but no change in E2F-1 and MDM2 protein levels (Fig. 5, A).
Both siRNAs together reduced the level of CK1 and p53 by
3-fold compared with controls (Fig. 5, A). The results show
that the p21 andMDM2 increases after CK1 siRNA treatment
were abolished when p53 was also attenuated. This implies that
the MDM2 and p21 increases after CK1 siRNA treatment
seem to be entirely dependent on p53 transactivation. The
E2F-1 decrease afterCK1 siRNA treatmentwas partially abro-
gated when p53 was also depleted by siRNA, however p53 was
FIGURE2.ACK1 inhibitor leads toadose-dependent increaseofp53 func-
tion and a decrease of E2F-1 protein levels. A375 cells were transfected
with increasing concentrations (10–60 M) of the CK1 inhibitor D4476 for
48 h (lanes 4–7). A DMSO solvent control (lane 2), a mock transfected control
(lane 3), and an untreated control (DMEM only; lane 1) were included. A, cell
lysates were examined by Western blotting with antibodies against the indi-
cated proteins. B, ratio of hyperphosphorylated pRB (upper bandon the blot)/
hypophosphorylated pRB (lower band) is defined by changes in mobility in
SDS-PAGE (26) and was quantified using Scion Image software.
FIGURE 3. Lack of effect of CK1 depletion on p53 protein stability. A375
cells were transfected with control siRNA (40 nM; lane 3) or CK1-specific
siRNA (40 nM; lane 4) for 72 h. A mock transfected control (lane 2) and an
untreated control (DMEM only; lane 1) were included. Protein levels were
determined by Western blotting with antibodies against the indicated
proteins.
CK1 andMDM2 Form an Active Signaling Complex
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only partially depleted by this treatment. To establish p53
dependence more clearly, we compared protein levels from
HCT116 wt and HCT116 p53/ cells, following D4476 treat-
ment (Fig. 5, B and C). In HCT116 wt cells (Fig. 5B), the p53,
MDM2, p21, and E2F-1 protein levels were affected in the same
manner as in A375 cells after D4476 treatment (Fig. 2A), which
indicated that these effects are not cell type-dependent. In
HCT116 p53/ cells after D4476 treatment, E2F-1 protein
levels still decreased in a dose-dependent manner (Fig. 5C). All
of these data suggest that the stabilization of E2F-1 observed
when CK1 is present is p53-independent. This stabilization
effect could operate by at least two different mechanisms: a
FIGURE 5. E2F-1 protein decrease following CK1 depletion using siRNA
or D4476 treatment is p53-independent. A, A375 cells were transfected
with control siRNA (80 nM; lane 3), CK1-specific siRNA (40 and 40 nM of siRNA
control; lane 4), p53-specific siRNA (40 and 40 nM of siRNA control; lane 5), or
both CK1 and p53 siRNA (40 nm each; lane 6) for 72 h. A mock transfected
control (lane 2) control and an untreated control (DMEM only; lane 1) were
included. Protein levels were determined by Western blotting with antibod-
ies against the indicated proteins. B andC, HCT116wt (B) andHCT116p53/
(C) cellswere transfectedwith increasingconcentrations (5–40M)of theCK1
inhibitor D4476 for 72 h. A DMSO solvent control, an untreated control
(DMEM only), and a mock transfected control were included. The protein
levels were determined byWestern blottingwith antibodies against the indi-
cated proteins. RNAi, RNA interference.
FIGURE 4. CK1 depletion using siRNA displays a synergistic effect with
ionizing radiation on E2F-1 destabilization. A375 cells were transfected
with control or CK1-specific siRNA (40 nM; lanes 5–8) for 72 h and treated
with (even-numbered lanes) or without (odd-numbered lanes) 5-gray x-ray
and cultured for a further 24 h. Amock transfected control (lanes 3 and 4) and
an untreated control (DMEM only; lanes 1 and 2) were included. A, protein
levels were determined byWestern blottingwith antibodies against the indi-
cated proteins. B, quantification of different protein levels were determined
with Scion Image software and normalized against -actin protein level
measured for each different blot. RNAi, RNA interference.
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direct effect of CK1 on E2F-1 and/or an indirect effect of
CK1mediated through MDM2.
CK1 Forms a Stable Multiprotein Complex with MDM2 in
Cells—MDM2 has been shown to interact with the CK1 iso-
form, which phosphorylates the latter on serine residues 240,
242, and 246 in the acidic domain (14). However, transfected
MDM2 has been shown not to bind to CK1 by immunopre-
cipitation (17). After DNA damage, p53 has also been shown
to bind CK1 and CK1 isoforms (18) and to be phosphory-
lated at some sites by CK1 (13) and by CK1 (12). To con-
firm the interaction spectrum of endogenous CK1 with our
different key proteins p53, MDM2, and E2F-1, we tested
whether endogenous CK1 co-immunoprecipitated with
endogenous MDM2, p53, and E2F-1. Surprisingly, the three
endogenous proteins showed significant binding to endoge-
nous CK1 (Fig. 6,A and B, lower panels, lane 6, and C, lane 8).
Although CK1 seemed to bind nonspecifically to the beads to
some extent (Fig. 6, C, lower panel, lane 4, and A, lower panel,
lane 2, respectively), with E2F-1 or MDM2 antibody bound to
the beads, the co-immunoprecipitated CK1 band was more
pronounced. Thus there appears to be stable complexes
between CK1 and p53, between CK1 and MDM2, and also
between CK1 and E2F-1 in unstressed A375 cells.
CK1 Inhibition or DepletionUsing siRNADisplays the Same
Effects as Nutlin-3 Treatment in wt Cells but Not in p53/
Cells—We set out to determine whether these modifications
following inhibition of CK1 expression or activity are similar
to the effects induced by other known p53 activating molecules
to identify themechanismof action ofCK1. The first targetwe
considered was MDM2 because of its previously documented
link with CK1. Treatment of A375 cells (Fig. 7A) or HCT116 wt
cells (Fig. 7B, lanes 1–4) with Nutlin-3 affected the MDM2,
p53, p21, and E2F-1 protein levels and phosphorylation status
of pRB in the same manner as CK1 inhibitor or siRNA treat-
ment. Nutlin-3 molecule binds in the p53-binding pocket of
MDM2 and displaces p53 from the complex. This results in p53
stabilization and p21 and MDM2 induction. Nutlin-3 affected
the E2F-1 protein levels to the same extent as CK1 siRNA
treatment. It has been shown recently that Nutlin inhibits the
binding between MDM2 and E2F-1, which promotes the
increased ubiquitination and subsequent proteosomal degra-
dation of E2F-1 by other ubiquitin ligases (19). Thus we can
conclude that CK1, through MDM2 phosphorylation activity
or interaction, in normal conditions, may promote the binding
of MDM2 with p53 and E2F-1. In the context of HCT116
p53/ cells (Fig. 7B, lanes 5–8), Nutlin-3 treatment did not
affect the E2F-1 protein level in the
same way that D4476 treatment did
in the absence of p53 (Fig. 5C). This
result highlights an interesting dif-
ference between the two drugs.
D4476 Treatment Induces Apop-
totic Cell Death of A375 Cells
(Measured by Accumulation of a
Sub-G0/G1 Cell Population)—After
CK1 siRNA or D4476 treatment,
A375 cells were observed to be pro-
liferating slower, if at all, compared
with controls, as if the treatment
induced cell cycle arrest or apopto-
sis. To test this hypothesis, we
stained the DNA of D4476-treated
A375 cells with propidium iodide
and analyzed the cell cycle distribu-
tion by flow cytometry (Fig. 8A).
FIGURE 6. A protein-protein interaction in cells between CK1 and
MDM2.A–C, A375cells analyzedby immunoprecipitationusingantibodies to
MDM2 (A), p53 DO1 (B), or E2F-1 (C). Co-immunoprecipitation was deter-
mined by Western blotting with anti-CK1 (A–C) and antibodies against the
immunoprecipitated proteins (MDM2 (A), p53 CM1 (B), and E2F-1 (C)). No
antibody immunoprecipitation controls (No Ab IP, lanes 1 and 2 (A and B) and
lanes 3 and 4 (C)) and immunoprecipitation controls without lysate (lanes 3
and 4 (A andB) and lanes 5 and 6 (C))were included. The flow-through (FT) and
the final eluate (E) were analyzed, along with the original lysate and the pre-
cleared lysate (lanes 1 and 2 (C)).
FIGURE7.Nutlin-3modulates the levels ofMDM2-bindingproteinsp53andE2F-1.A375 (A), HCT116wt (B,
lanes 1–4), and HCT116 p53/ (B, lanes 5–8) cells were treated for 24 hwith 5 or 10MNutlin-3 (lanes 3 and 4,
respectively). ADMSO solvent control (lane 1) and anuntreated control (DMEMonly; lane 2) were included. The
cell lysates were examined by Western blotting with antibodies against the indicated proteins.
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Cell cycle distribution profiles indi-
cated that, upon increasing the
addition of the drug to A375 cells,
the incidence of a sub-G1 fraction
(less than normal diploid DNA
content) increased, implying a
possible apoptotic effect of the
CK1 inhibitor D4476 on cells.
Interestingly, cell cycle distribu-
tion profiles upon Nutlin-3 treat-
ment exhibited, to a smaller extent,
an increase of the sub-G1 fraction
(Fig. 8B). Moreover, Nutlin-3 was
shown to display pro-apoptotic
activity in mantle cell lymphoma
(20), highlighting another com-
mon point between D4476 and
Nutlin-3 treatment.
Apoptotically Induced Cell Death
Following D4476 Treatment Is p53-
independent—Taking into account
the increase of a sub-G1 cell popula-
tion following CK1 inhibition, we
testedwhether this protection against
apoptotic events was p53-dependent
or -independent in the same manner
as previously, using HCT116 wt and
p53/ cells. As with A375 profiles
(Fig. 8), upon increasing the addi-
tion of D4476, HCT116 wt cell cycle
distribution profiles showed the
appearance of a sub-G1 fraction
(Fig. 9A). Interestingly, this apopto-
tic cell population was still observed
in HCT116 cells in which p53 is
absent (Fig. 9B). These findings sug-
gest that the CK1 antagonist D4476
might be an effective agent in cancer
cells with or without wild type p53,
as has been suggested previously for
Nutlin-3 (20).However, p53/ and
wt cells displayed different cell cycle
profiles after Nultin-3 treatment
(Fig. 10). Indeed in both HCT116
cell lines, only a slight increase of
a sub-G0/G1 population was ob-
served, especially in p53/ cells.
However, wt cell profiles (Fig. 10A)
displayed a large increase in a G0/
G1 cell population after Nutlin-3
treatment.
DISCUSSION
p53 tumor suppressor is a short
lived transcription factor that is sta-
bilized and activated in response to
a wide variety of cellular stresses
such asDNAdamage. The oncopro-
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tein MDM2 is a critical regulator of p53 that acts by mediating
the ubiquitination and proteasome-dependent degradation of
p53. The ability of MDM2 to modulate p53 levels is tightly
regulated through a variety of protein-protein interactions and
post-translational modifications such as phosphorylation in
response to a range of cellular stresses.
Our recent data highlighted that CK1 is the major enzyme
that catalyzes serine 20 site phosphorylation of p53 in DNA
virus-infected cells. This suggests a previously undefined role
for CK1 in linking the p53 checkpoint pathway to the cellular
response to DNA virus infection (13). Moreover, several serine
residues of MDM2 have been shown to be phosphorylated by
CK1 under normal conditions (14), and this phosphorylation
is required for efficientMDM2-mediated p53 degradation. The
present study investigates the link between CK1 and the p53-
MDM2pathway in cycling cells to further our understanding of
the role of CK1 in regulating p53/MDM2/E2F-1 signal trans-
duction pathways.
The data presented in our current report indicate that block-
ing MDM2 with Nutlin-3 or depleting/inhibiting CK1 gener-
ated the same effects: an increase in the p53, MDM2, and p21
protein levels and a decrease in the E2F-1 protein level (Table
2). Furthermore, the CK1 inhibitor D4476 or Nutlin-3 treat-
ment led to the accumulation of an apoptotic sub-G0/G1 cell
population. Based on the findings reported in this manuscript
and other studies, we propose that one possible molecular
mechanism through which the p53/MDM2 association is reg-
ulated would be due to the recruitment of protein kinases, such
as CK1 studied in this report or CK1, which is known to
phosphorylate the acidic domain of MDM2 in unstressed con-
ditions (14). The down-regulation of p53 under normal con-
ditions prevents the triggering of apoptosis but also prevents
p21 from inhibiting cyclinCDK complexes that phosphor-
ylate pRB, thereby releasing E2F-1 and promoting cell cycle
progression. Based on this model (Fig. 11), the inhibition of
CK1would be expected to lead to the dephosphorylation of
MDM2, which in turn would lead to an increase of p53,
MDM2, and p21 protein levels and consequently would trig-
ger apoptosis (Figs. 8–10).
Our results also suggest thatCK1 interactswithMDM2and
that both the CK1 inhibitor D4476 andNutlin-3 down-regulate
E2F-1 protein levels. In a previous study (19), the loss of E2F-1
following Nutlin treatment seemed to be mediated by its
increased ubiquitination and subsequent proteosomal degra-
dation. MDM2 increases the E2F-1 protein half-life by inhibit-
ing the ubiquitination of E2F-1 by displacing the E3 ubiquitin
ligase SCFSkp2 from E2F-1 (15). We can venture the hypothesis
that phosphorylation ofMDM2 by CK1 should allow its bind-
ing with E2F-1, which is thus protected against degradation.
Because the phosphorylation of MDM2 by CK1 appears to
permit the binding of MDM2 with both p53 and E2F-1, we can
infer that p53 and E2F-1 bind to the same MDM2-binding
pocket. Indeed it was previously demonstrated that MDM2
shows a direct association with a region of E2F-1 that shares a
substantial similarity with the MDM2-binding domain of p53
(21).
CK1 was also shown to interact with E2F-1, and destabili-
zation of E2F-1 following CK1 siRNA treatment or inhibition
was shown to be p53-independent. We can also hypothesize
that CK1 in complex with MDM2 may also phosphorylate
E2F-1, which should result in E2F-1 stabilization, in a similar
way as phosphorylation of E2F-1 by ATM/ATR and Chk1/
Chk2 kinases after DNA damage (22). Under these conditions,
the inhibition of CK1 would be expected to lead to a decrease
of E2F-1 protein levels, which is consistent with our findings.
Finally, we can speculate that the observed simultaneous desta-
bilization of E2F-1 afterCK1 siRNA treatment or inhibitionwas
mediated indirectly by the dephosphorylation of MDM2, as
well as maybe directly by the dephosphorylation of E2F-1 itself,
thus explaining the synergistic effect of CK1 siRNA treatment
and ionizing radiation on E2F-1 level. Finally, the CK1 antago-
nist D4476 treatment induced apoptosis in cancer cells with or
without the presence of p53, which is reminiscent of a previous
report where Nutlin-3 was shown to generate a similar re-
sponse inmantle cell lymphoma (20). BecauseD4476 treatment
down-regulated E2F-1 protein level in a p53-independentman-
ner, we can suggest that the apoptotic effect of CK1 inhibition is
due to the loss of E2F-1.
The binding between p53 and CK1 highlighted in this study
should allow the phosphorylation of p53 at some sites, such as
threonine 18 after DNA damage (12) and serine 20 after DNA
virus infection (13). It was also proposed that the interaction of
CK1 with the multiprotein docking sites in the DNA-binding
domain of p53 allows its subsequent binding to and phosphor-
ylation of serine 20 and/or threonine 18 sites within the N-ter-
minal transactivation domain of p53. We therefore postulate
that under normal conditions, CK1 can bind to p53 but can only
fully bind to and phosphorylate p53 after damage triggered by
different stresses. Moreover, the acidic domain of MDM2 has
been suggested to be hypophosphorylated in response to ioniz-
ing radiation, which contributes to p53 stabilization (23).
Therefore, CK1 may act as a key switch; in normal condi-
tions (Fig. 11), CK1 promotes p53 degradation and inhibi-
tion by MDM2, but after DNA damage, CK1 phosphorylates
p53, which leads to a disruption of MDM2p53 complexes
and thus p53-mediated tumor suppression consequences on
the cells. It appears that CK1 or other kinases are recruited
into specific complexes under different conditions, which
can influence the substrate selectivity of the kinase. CK1
docking to MDM2 should phosphorylate or maintain MDM2
in a form that favors MDM2 activity. Thus CK1 and MDM2
could form a complex that can induce a genetic signal that
controls the transcription factors E2F-1 and p53 (Fig. 11). For a
better understanding of p53/MDM2 pathways, we need to
FIGURE 8. Analysis of the effects of the CK1-specific inhibitor D4476 andMDM2 inhibitor Nutlin-3 on cell cycle distribution of A375melanoma cells.
A, A375 cells were transfected with increasing concentrations (10–40 M) of the CK1 inhibitor D4476 for 72 h. A DMSO solvent control, an untreated control
(DMEM only), and a mock transfected control (only the last one is shown here) were included. B, A375 cells were treated for 24 h with 5 or 10 M Nutlin-3. A
DMSO solvent control and anuntreated controlwere included. The cellswere fixed in ethanol and then stainedwith propidium iodide. Cell DNA contentswere
determined by FACS and analyzed with FlowJo7 software.
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FIGURE9.Analysis of theeffects of theCK1-specific inhibitorD4476oncell cycledistributionofHCT116wtandp53/ cells.HCT116wt (A) andHCT116
p53/ (B) cells were transfectedwith increasing concentrations (10–40M) of the CK1 inhibitor D4476 for 72 h. ADMSO solvent control, an untreated control
(DMEM only), and a mock transfected control (only the last one is shown here) were included. The cells were fixed in ethanol then stained with propidium
iodide. Cell DNA contents were determined by FACS and analyzed with FlowJo7 software.
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FIGURE 10. Analysis of the effects of theMDM2 inhibitor Nutlin-3 on cell cycle distribution of HCT116 wt and p53/ cells. HCT116 wt (A) and HCT116
p53/ (B) cells were treated for 24 h with 5 or 10 M Nutlin-3. A DMSO solvent control and an untreated control (DMEM only) were included. The cells were
fixed in ethanol then stained with propidium iodide. The cell DNA contents were determined by FACS and analyzed with FlowJo7 software.
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determine how the MDM2CK1 complex evolves after DNA
damage and other stresses and resolve how CK1 is converted
from an inhibitor of p53 to an activator of p53. Because theCK1
signaling pathway seems to coordinate p53/MDM2/E2F-1 in
normal conditions as well as in response to various stresses
applied to cells, CK1 could be an interesting target in the fight
against cancer.
More interestingly, theCK1 inhibitorD4476was shown to be
efficient not only in tumor cells with wild type p53 but also in
p53-null cells. Indeed, the importance of p53-independent
functions that are essential for controlling tumorigenesis has
recently been taken into consideration (24). For instance,
MDM2 can influence apoptosis through its control of E2F-1.
Thus MDM2 inhibition could increase the efficiency of cancer
drug treatment, even in cells lacking p53. Another interesting
point is that CK1 has been directly involved in regulating the
p53 pathway by phosphorylation of MDMX, a recently identi-
fied homolog of MDM2 that can bind to p53 and inhibit its
transcription function but that is not able to promote p53 ubiq-
uitination or degradation (17). Because the MDMX/p53 inter-
action appears not to be disrupted efficiently by Nutlin-3 (25),
developing a CK1 inhibitor against both MDM2 and MDMX
could be a very attractive proposition. The next challenge will
also be the generation of inhibitors specifically designed to
inhibit one of the CK1 isoforms and to prevent the interaction
of a CK1 isoform with defined substrates such as MDM2 and
MDMX, without affecting its ability to phosphorylate and
interact with regulatory proteins of other cellular pathways.
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FIGURE 11. TheMDM2 and CK1 complex form a genetic signal that reg-
ulates p53 and E2F-1 protein stability. Under normal conditions, CK1
interacts with MDM2 (condition 1), which promotes its binding to p53 and
leads to p53 ubiquitination and degradation (condition 2) but also to inhibi-
tion of transactivation of p53 targets, p21 for example (condition 3). This is
supported by our data: Nutlin-3 or CK1 depletion/inhibition stabilize p53 and
p21, suggesting apharmacologically similar interactionbetweenp53and the
MDM2CK1 complex. The interaction betweenMDM2 andCK1 should also
allow the binding between E2F-1 and MDM2, an interaction that has been
shown to prevent the degradation of E2F-1 by other E3-ligases (condition 4).
This is also supportedby the samedata, but it is yet tobedeterminedwhether
the MDM2-CK1 interaction and in turn whether CK1 binding to E2F-1 is
phosphorylation-dependent or kinase docking-dependent. Under normal
conditions, these phosphorylation or docking events mediated by CK1
therefore promote cell cycle progression. After DNA damage, the loss of the
complex between MDM2 and CK1 could explain the destabilization of
E2F-1. Alternatively, the MDM2CK1 complex might be inactivated post-
translationally, for example by changes in phosphorylation status. In addi-
tion, the destabilization of E2F-1 might be partly due to a loss of binding
between CK1 and E2F-1.
TABLE 2
Summary of protein level changes in response to the main different
conditions tested and on the different cell lines, A375 and/or
HCT116: CK1 siRNA treatment, D4476 treatment, Nutlin-3, and
x-ray
CK1
siRNA X-ray D4476 Nutlin-3
D4476 on
p53/ cells
Nutlin-3 on
p53/ cells
p53 1 1 1 1 – –
p21 1 1 1 1 – –
MDM2 1 1 1 1 2 3
E2F-1 2 2 2 2 2 3
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